dr. heather wakelee on what to do when resistance to egfr tkis emerges
Published 8 years ago • 398 plays • Length 1:36Download video MP4
Download video MP3
Similar videos
-
1:27
dr. wakelee discusses egfr tkis in lung cancer
-
1:57
dr. wakelee on benefits of osimertinib in egfr-mutant nsclc treatment
-
1:29
dr. wakelee on available treatments following tumor progression in lung cancer
-
2:19
dr. wakelee on detection of egfr t790m mutation in nsclc
-
2:03
dr. wakelee on rationale to explore osimertinib with concurrent chemotherapy in egfr-mutant nsclc
-
36:30
palliative care in liver disease with dr fiona findlay
-
49:45
health, aging, and disease - it's all about energy - part 1
-
59:21
when breath becomes air: a conversation about life, death, and humanity in health care
-
2:03
dr. west on considering factors for egfr tkis in nsclc
-
0:55
dr. heather wakelee discusses the avaperl trial
-
0:50
treating patients with egfr-mutant lung cancer with targeted therapies
-
1:33
dr. wakelee on continued maintenance in lung cancer
-
1:16
dr. wakelee on first-line therapy for egfr-mutant lung cancer
-
1:01:37
frontiers in oncology - heather wakelee, md
-
5:16
treatment options for mnsclc after progression
-
1:19
dr. wakelee on combining targeted agents for the treatment of lung cancer
-
1:32
dr. wakelee on immunotherapy versus targeted agents in nsclc
-
1:27
dr. heather wakelee on "which molecular marker tests do you seek?"
-
2:43
what you need to know about lung cancer research
-
1:52
dr. wakelee discusses adjuvant therapy in elderly nsclc patients
-
1:43
heroes work here: dr. marianne holler, palliative medicine physician
-
3:24
what's the status and potential utility of cabozantinib in lung cancer?